Groupon reported Q1 2026 on May 8. Two filings matter more than the print: a 10-K disclosing a 1.79% passive stake in SumUp, and three Form 4s showing the CEO, CFO, and COO each made open-market purchases on May 1, totaling $9.3M at ≈$10.58.

What the filing shows

Q1 missed. Billings -1% YoY against flat-to-up guidance. Adjusted EBITDA $12.8M vs $13-15M guide. GAAP swung from +$8M Q1 2025 to -$12.6M. The enterprise channel went negative for the first time in five quarters. Active customers grew +5% but units fell -5% — purchase frequency declining.

Management reaffirmed FY 2026 adj EBITDA at $70-75M and FCF ≥$60M. H1 tracks ≈$26M, so H2 needs ≈$46.5M against H2 2025's $38.4M — a +21% acceleration. Three levers, none contracted: a 15% headcount reduction pending board approval, AI-driven marketing efficiency, and enterprise channel recovery.

The Form 4s (May 1, code P) are coordinated open-market purchases at cycle lows. Buyback is parallel: $29.7M deployed since March 10 at $10.58 average, with $215M authorization remaining against a $600M market cap.

The 10-K confirms 1.79% ownership of SumUp, carried at near-zero after prior impairments. Bloomberg reported April 14 that SumUp has mandated DB / GS / JPM / Jefferies for a London IPO targeting $10-15B. At the $12.5B base case, GRPN's stake is worth $224M — 37% of current market cap.

The 2027 convertible debt wall is also smaller than the bear narrative implied. Per the 10-K, only $47.3M of 2027 Notes remain; $150M was exchanged into 2030 Notes in July 2025. Cash covers near-term maturities ($81M including the $33.7M 2026 Notes) at 2.8x.

What the market thinks

Sell-side targets span Goldman $10 (Sell) to Northland $40+ (Buy). The $30 dispersion on a $16 stock is consistent with the analyst set splitting on a single question: whether to mark the SumUp stake. Goldman's target implies operating-only valuation at ≈5x EBITDA; Northland's $40 requires SumUp at the high end of the range plus operating expansion.

Short interest is 59.2% of float, 6.7 days to cover. The stock is +40% over the past month, suggesting a partial squeeze is already underway. β to SPY is 0.11 — this trades on its own story.

Why the gap exists

The stake is below the line in operating models. Post-impairment carrying value is near-zero; sell-side won't mark to a private valuation until the IPO prints. The Bloomberg bookrunner mandate (DB / GS / JPM / Jefferies) is concrete but recent (April 14) and not yet reflected in any analyst SOTP we found.

Separately, the operating bear narrative has been reframed but not re-priced. Q1 2026 cohort data: YELP advertising locations -6%, ANGI pulled FY guidance entirely. The local-services-discovery cohort is universally weak. Meanwhile META (8M+ SMB advertisers on AI tools) and SNAP (SMBs tripled in three years) report SMB strength. So the weakness is concentrated in review/listing-driven local discovery, not generalized SMB ad pullback. GRPN's enterprise channel decline is sectoral, but has been priced as idiosyncratic execution failure.

Risks (ranked)

1. SumUp IPO pulls or values <$6B. Half the expected return disappears. Trigger: SumUp postpones, down-round, or leadership change. P≈20%.
2. Operating decline is structural, not cyclical. Google AI Overviews + meta-style SMB platforms displace local-discovery cohort entirely. Bear -25%, tail -45%. P≈35% combined.
3. Headcount cut delayed or savings <$10M annualized. H2 acceleration unsupported, FY guide cut mid-year.
4. Secondary insider sale at $14-17. Contradicts the May 1 floor signal.
5. Convertible dilution if stock rallies sharply. $244M of 2030 Notes at 4.875% are convertible; deep OTM today but caps the right tail.

Catalysts

What would change our mind

• SumUp IPO pulled or further written down → thesis breaks
• YELP/ANGI Q2 ad metrics worse than Q1 (-7% or beyond) → cohort structural, multiple compression accelerates on the operating business
• GRPN board fails to approve 15% cut by August earnings → H2 acceleration unsupported
• Any of the three May 1 buyers sells at $14-17 → coordinated floor signal contradicted
• SumUp prices at $15B+ → bull thesis confirmed; the operating uncertainty becomes irrelevant to outcome

SOTP at varying multiple × SumUp combinations ($/share)

EBITDA on $72.5M midpoint guide. Equity = operating EV + SumUp stake − $99.5M net debt, divided by 35.6M shares. Current $16.87 corresponds to ≈6.5-7x with base SumUp. The insider buy basis at $10.58 corresponds to 5x + weak SumUp — the bear-case fair value.

Evidence

What this is

A catalyst-anchored position on an unpriced asset, with insider-validated downside support, riding a soft operating story through a sectoral air pocket. Forward EV is +4% over 12mo with high variance — not a Sharpe trade. Most of the expected return comes from SumUp monetization; operations contribute roughly zero in expectation; cohort weakness is a modest negative.

If SumUp doesn't monetize within 18 months, the thesis E[r] collapses to near zero. The trade lives or dies on that single asset.